Universiteit Gent

Vib Vzw

La Jolla Institute for Allergy and Immunology

Ghent University

Arcarios B.v.

Katholieke Universiteit Leuven, Ku Leuven R&d

University of Gent

Dirk Elewaut

Serge Van Calenbergh

August Verbruggen

Leander Huyghe

Dieter Deforce

Els Louagie

Jeroen Raes

Stijn Lambrecht

Dirk Zajonc

Nele Juchtmans

Ruth Wittoek

Bert Vander Cruyssen

Sandrine Aspeslagh

Joren Guillaume

August Lodewijk Verbruggen

Peter Brouckaert

Nora Pauwels

Bart De Spiegeleer

Anton De Spiegeleer

Evelien Wynendaele

Nele Van Den Noortgate

Raul Yhossef Tito-Tadeo

Geert Huys

Lars Vereecke

Marie Joossens

The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of &#x3b1;-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.

Sphingamide compounds and methods for binding iNKT cells

The disclosure provides compositions and methods comprising a sialoadhesin binding moiety for treating metabolic and genetic bone disease, especially for treating a bone disorder of hyper-resorption of bone and/or enhanced activation of osteoclasts.

Method of treating bone disease

This invention relates to carbamate-containing or thiocarbamate-containing galacto-pyranosyl compounds useful as therapeutic agents and being represented by the structural formula (II), wherein: X is O or S, R is selected from the group consisting of Calkyl, Ccycloalkyl, aryl-Calkyl, heterocyclyl-Calkyl, cycloalkyl-Calkyl, aryl and heterocyclyl, wherein R is optionally substituted with one or more R; R, R, R, Rand Rare independently selected from the group consisting of hydroxyl and protected hydroxyl groups; Ris selected from the group consisting Calkyl and arylalkyl; Ris Calkyl; and each Ris independently selected from the group consisting of halogen, hydroxy, trifluoromethyl, trifluoromethoxy, Calkoxy, Calkyl, cyano, methylthio, phenyl, phenoxy, chloromethyl, dichloromethyl, chloro-difluoromethyl, acetyl, nitro, benzyl, heterocyclyl and di-Calkyl-amino, or a pharmaceutically acceptable salt thereof. 

Galactopyranosyl derivatives useful as medicaments

In vitro methods for differential diagnosis of spondyloarthropathy are disclosed which involve determining the levels of GDF15 in biological samples.

GDF15 as a differential marker for spondyloarthropathy

The present invention provides a scoring system to monitor natural or drug-modified disease progression in erosive inter-phalangeal finger joint osteoarthrits and the use of said scoring system to identify and value drugs with anticatabolic and/or repair promoting potential.

Scoring system to monitor natural or drug-modified disease progression in 'erosive osteoarthritis' of the interphalangeal finger joints

This invention relates to novel &#x3b2;-cyclodextrin polysulfate compounds comprising from one to three 2-carboxyethyl substituents, and at least two sulfates groups per glucopyranose unit, which are useful as active ingredients for the treatment and/or prophylaxis of degenerative joint diseases, osteoarthritis, articular rheumatism, arthrosis or degenerative arthritis, or for the treatment of heparin-induced thrombocytopenia, or for cartilage repair or connective tissue repair.

Carboxyethylated cyclodextrin polysulfates useful as medicaments

The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide.

Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide

Growing community of inventors

Heusden, Belgium

Dirk Elewaut